Pioneering novel antibody-based cancer therapies informed by large-scale patient-derived biology.
OncoPrecision has raised $4.5M in total funding. The most recent round was Seed. The last funding was announced in November 2025.
OncoPrecision's investors include SOSV, Creative Ventures, SOSV SF & NY (Fka IndieBio), New York Ventures, GRID EXPONENTIAL.
OncoPrecision is headquartered in New York, United States.
Pioneering novel antibody-based cancer therapies informed by large-scale patient-derived biology.
OncoPrecision is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"OncoPrecision — Funding & Investors." VCBacked, November 24, 2025, https://www.vcbacked.co/company/oncoprecision. Accessed August 14, 2026.
VCBacked. (2025). OncoPrecision — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/oncoprecision
{{cite web |title=OncoPrecision — Funding & Investors |url=https://www.vcbacked.co/company/oncoprecision |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated